You are here

Development of a Novel Anti-HIV Oligonucleotide

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 AI38788-01,
Agency Tracking Number: 29153
Amount: $98,800.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
9391 Grogans Mill Road
The Woodlands, TX 77380
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Thomas Wallace
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

AIDS is a fatal disorder of the immune system caused by the HIV and is a widespread epidemic. The lobjective of this work is to treat human AIDS patients with a novel oligonucleotide (T30177) that haanti-HIV activity. We will perform preclinical animal pharmacology studies, including pharmacokinetiand toxicity studies in mice. One of these aims includes investigating a novel in vivo route of admioligonucleotides. Although there are a number of drugs that are currently available for the treatmenhave limited effectiveness and only delay the progression to death of AIDS patients. There is a greadevelopment of more effective and novel drugs for the treatment of AIDS. T30177 may provide significpresently available HIV drugs because it has a novel mechanism of action, it is active against AZT-rbeen shown in pilot animal studies to have a long half-life, good stability, and low toxicity.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government